ArticleJournal of magnetic resonance imaging : JMRI2026
Automated Ultrashort Echo Time (UTE) MRI Low Signal Volume Analysis in Stable Pediatric Cystic Fibrosis and After Elexacaftor/Tezacaftor/Ivacaftor Therapy.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "Automated Ultrashort Echo Time (UTE) MRI Low Signal Volume Analysis in Stable Pediatric Cystic Fibrosis and After Elexacaftor/Tezacaftor/Ivacaftor Therapy".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUltrashort echo time (UTE) MRI overcomes the low signal intensity and short T PURPOSE: To explore short-term repeatability and sensitivity to treatment of low signal volume (LSV) from UTE MRI in pediatric CF. STUDY-TYPE: Single-site, retrospective, longitudinal. SUBJECTS: Thirteen participants with stable CF (6M/7F, median age = 15 years old) were scanned at baseline and 1-month to evaluate short-term repeatability. Subsequently, 14 CF participants (7M/7F median age = 16 years old) were scanned pre- and 1-month post-initiation of elexacaftor/tezacaftor/ivacaftor (ETI). FIELD STRENGTH/SEQUENCE: Three-dimensional stack-of-spirals for UTE, 2-dimensional gradient-echo for hyperpolarized xenon (Xe-MRI), 3-dimensional gradient-echo for thoracic cavity estimation at 3 T. ASSESSMENT: LSV was analyzed from UTE MRI. Same-day spirometry, multiple-breath washout, and Xe-MRI were also performed to compare to LSV. STATISTICAL TESTS: Differences were assessed with the Wilcoxon matched-pairs signed-rank test. Bland-Altman analysis and the Intraclass Correlation Coefficient (ICC) were used to assess 1-month repeatability in stable CF. Relationships between measures were assessed with Spearman correlation. p < 0.05 was considered significant.
resultsBaseline LSV was correlated with forced expiratory volume in 1 s (FEV DATA
conclusionLSV analysis was feasible and repeatable in pediatric CF over a 1-month period. LSV was significantly reduced 1-month after ETI treatment, indicating sensitivity to reduced gas trapping, hyperexpansion, and obstruction. EVIDENCE LEVEL: 4. TECHNICAL EFFICACY: 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.